Sangamo, Pfizer partner for ALS therapy

Sangamo Therapeutics Inc. (NASDAQ:SGMO) and Pfizer Inc. (NYSE:PFE) partnered to develop a therapy using Sangamo's zinc finger protein transcription factor (ZFP-TF) gene regulation technology to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of chromosome 9 open reading frame 72 (C9orf72).

Sangamo will receive $12 million up front and is eligible for up to $150 million in milestones, plus tiered royalties...